Chemoblast is consists of Vinblastine, is a chemotherapy medication derived from the periwinkle plant (Catharanthus roseus). It belongs to the vinca alkaloid class of drugs and is primarily used for treating various cancers, including Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, breast cancer, testicular cancer, and Kaposi’s sarcoma. Vinblastine works by inhibiting microtubule formation, preventing cancer cells from dividing and proliferating. Vinblastine remains a cornerstone in cancer chemotherapy, particularly for Hodgkin’s lymphoma, testicular cancer, and Kaposi’s sarcoma. Its role in combination regimens has significantly improved survival rates for many patients. However, its myelosuppressive effects necessitate careful monitoring. With ongoing advancements in drug delivery and combination therapies, vinblastine’s effectiveness may continue to improve in the coming years.
Vinblastine is a mitotic inhibitor that functions by binding to tubulin, a protein essential for microtubule formation. Microtubules play a crucial role in cell division, and by preventing their assembly, vinblastine halts mitosis in the metaphase, leading to cancer cell death.
Microtubule Disruption: Prevents mitotic spindle formation, blocking cell division.
Apoptosis Induction: Leads to programmed cell death in rapidly dividing cancer cells.
Reduced Angiogenesis: Inhibits the formation of new blood vessels that feed tumors.
Hodgkin’s Lymphoma – Used in combination chemotherapy regimens like ABVD (Adriamycin, Bleomycin, Vinblastine, and Dacarbazine).
Non-Hodgkin’s Lymphoma – Effective in slowing disease progression.
Testicular Cancer – Part of BEP (Bleomycin, Etoposide, and Platinum-based therapy).
Breast Cancer – Used in advanced-stage or recurrent cases.
Kaposi’s Sarcoma – Treats aggressive cases in immunocompromised patients (e.g., HIV/AIDS-related Kaposi’s sarcoma).
Bladder Cancer & Lung Cancer – Investigated for efficacy in metastatic settings.
Typical Dosages:
Lymphomas: 6 mg/m² IV every 7-14 days.
Testicular Cancer: 3 mg/m² IV weekly.
Breast Cancer & Kaposi’s Sarcoma: Dosage varies depending on combination regimens.
Pediatric Dosing: Adjusted based on body surface area (BSA) and tolerance.
Hodgkin’s Lymphoma (ABVD Trial):
Improved survival rates with ABVD vs. older regimens.
High complete remission rates (~80%).
Testicular Cancer (BEP Regimen Studies):
High cure rates (~90%) in early-stage disease.
Kaposi’s Sarcoma (AIDS-Related Trials):
Effective in reducing tumor burden.
Common Side Effects:
Bone Marrow Suppression: Leads to leukopenia (low white blood cell count), increasing infection risk.
Gastrointestinal Issues: Nausea, vomiting, constipation.
Neuropathy: Mild to moderate peripheral neuropathy.
Alopecia: Temporary hair loss.
Fatigue & Weakness.
Serious Side Effects:
Severe Myelosuppression: Can lead to life-threatening infections.
Neurotoxicity: Less common than vincristine but can still occur.
Extravasation Risk: Severe local tissue necrosis if it leaks outside the vein.
Contraindications:
Severe leukopenia (low WBC count).
Hypersensitivity to vinca alkaloids.
Pregnancy and breastfeeding.
Precautions:
Renal & Hepatic Impairment: Dose adjustments required.
Neuropathy Risk: Monitor for tingling or numbness.
Vaccinations: Avoid live vaccines during therapy.
CYP3A4 Inhibitors (e.g., Ketoconazole, Erythromycin): Increase vinblastine levels, enhancing toxicity.
CYP3A4 Inducers (e.g., Rifampin, Carbamazepine): Reduce vinblastine efficacy.
Other Chemotherapy Agents: Increased bone marrow suppression when combined with cisplatin or doxorubicin.
Antifungal Medications (Itraconazole, Fluconazole): May exacerbate side effects.
Store at 2-8°C (Refrigerated).
Protect from light to prevent degradation.
Use within prescribed time after dilution.
Safe disposal required due to cytotoxic nature.
Chemoblast is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult(Female) |
|
Geriatric |
|
Adult |
|
Adult(Male) |
|
13 - 18 years (Adolescent) |
|
Is the use of Chemoblast safe for pregnant women?
Chemoblast can cause severe side effects if taken during pregnancy, so, pregnant women should talk to their doctor before taking it.
Is the use of Chemoblast safe during breastfeeding?
Taking Chemoblast may lead to serious side effects if you are breastfeeding. Chemoblast should not be taken by breastfeeding women unless prescribed by the doctor.
What is the effect of Chemoblast on the Kidneys?
Chemoblast is completely safe for kidneys.
What is the effect of Chemoblast on the Liver?
Chemoblast may cause harmful effects on liver. if you feel it's having any such effect, then stop taking this drug, and restart only on your doctor's advice.
What is the effect of Chemoblast on the Heart?
Chemoblast is not harmful for the heart.
Chemoblast should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
If you are suffering from any of the following diseases, you should not take Chemoblast unless your doctor advises you to do so -
Is this Chemoblast habit forming or addictive?
Chemoblast is not addictive in nature.
Is it safe to drive or operate heavy machinery when consuming?
After taking Chemoblast, you should not drive or work on any heavy machine, as Chemoblast can make you drowsy.
Is it safe?
Yes, Chemoblast is safe but you must consult your doctor before taking it.
Is it able to treat mental disorders?
No, the use of Chemoblast in mental disorders is not effective.
Interaction between Food and Chemoblast
Taking Chemoblast with food does not cause any problems.
Interaction between Alcohol and Chemoblast
No research has been done on this till date. Therefore, it is not known what the effect of taking Chemoblast with alcohol will be.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 865